The landscape of nanoparticle-based siRNA delivery and therapeutic development
Five small interfering RNA (siRNA)-based therapeutics have been approved by the Food
and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and …
and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and …
[HTML][HTML] Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
V Mallenahalli Neeekantappa, A Kamath… - Medicina, 2024 - mdpi.com
Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal stem cell disease characterized by
intravascular hemolysis due to the targeting of affected red blood cells by the complement …
intravascular hemolysis due to the targeting of affected red blood cells by the complement …
Pozelimab/cemdisiran. Complement protein C5 inhibitor, Treatment of complement-mediated diseases
M Griffin - Drugs of the Future, 2023 - access.portico.org
Background Pozelimab, a fully human IgG4 monoclonal antibody, administered
intravenously or subcutaneously, binds at C5 in the terminal complement cascade and halts …
intravenously or subcutaneously, binds at C5 in the terminal complement cascade and halts …